Literature DB >> 15969741

Multiple calcium channels and kinases mediate alpha7 nicotinic receptor neuroprotection in PC12 cells.

Ke Ren1, Viviana Puig, Roger L Papke, Yoshihito Itoh, Jeffrey A Hughes, Edwin M Meyer.   

Abstract

alpha7 Nicotinic receptors are calcium permeant and provide neuroprotection against many insults. We investigated the roles of intracellular calcium ions and downstream calcium channels in this protection. The alpha7 agonist GTS-21 prevented pheochromocytoma cell death induced by nerve growth factor + serum deprivation over a 3-day interval. This effect was blocked by the intracellular calcium chelator 1,2-bis(2-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid in a manner that did not appear to involve changes in receptor density. 1,2-Bis(2-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid blocked GTS-21-induced protein kinase C activation, a necessary process for protection. The insositol triphosphate calcium-channel blocker xestospongin C and the phospholipases C inhibitor U-73122 blocked protection, ryanodine partially attenuated protection, but the L-type channel antagonist nifedipine had no effect. ERK1/2 but not JNK and p38 were activated by GTS-21, and the ERK phosphorylation inhibitors PD98059 and U0126 blocked protection.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15969741     DOI: 10.1111/j.1471-4159.2005.03223.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  24 in total

Review 1.  Positive and negative effects of alcohol and nicotine and their interactions: a mechanistic review.

Authors:  Laura L Hurley; Robert E Taylor; Yousef Tizabi
Journal:  Neurotox Res       Date:  2011-09-20       Impact factor: 3.911

Review 2.  Targeting nicotinic receptors for Parkinson's disease therapy.

Authors:  Maryka Quik; Tanuja Bordia; Luping Huang; Xiomara Perez
Journal:  CNS Neurol Disord Drug Targets       Date:  2011-09-01       Impact factor: 4.388

Review 3.  Neuronal nicotinic receptors as novel targets for inflammation and neuroprotection: mechanistic considerations and clinical relevance.

Authors:  Merouane Bencherif
Journal:  Acta Pharmacol Sin       Date:  2009-06       Impact factor: 6.150

4.  Boosting Endogenous Resistance of Brain to Ischemia.

Authors:  Fen Sun; Stephen R Johnson; Kunlin Jin; Victor V Uteshev
Journal:  Mol Neurobiol       Date:  2016-02-24       Impact factor: 5.590

Review 5.  Alterations in Cholinergic Pathways and Therapeutic Strategies Targeting Cholinergic System after Traumatic Brain Injury.

Authors:  Samuel S Shin; C Edward Dixon
Journal:  J Neurotrauma       Date:  2015-06-29       Impact factor: 5.269

Review 6.  Looking below the surface of nicotinic acetylcholine receptors.

Authors:  Clare Stokes; Millet Treinin; Roger L Papke
Journal:  Trends Pharmacol Sci       Date:  2015-06-08       Impact factor: 14.819

7.  Activation of developmental nuclear fibroblast growth factor receptor 1 signaling and neurogenesis in adult brain by α7 nicotinic receptor agonist.

Authors:  Sridhar T Narla; Ilona Klejbor; Barbara Birkaya; Yu-Wei Lee; Janusz Morys; Ewa K Stachowiak; Dorota Prokop; Merouane Bencherif; Michal K Stachowiak
Journal:  Stem Cells Transl Med       Date:  2013-09-06       Impact factor: 6.940

Review 8.  Potential Therapeutic Application for Nicotinic Receptor Drugs in Movement Disorders.

Authors:  Maryka Quik; James T Boyd; Tanuja Bordia; Xiomara Perez
Journal:  Nicotine Tob Res       Date:  2019-02-18       Impact factor: 4.244

Review 9.  Positive allosteric modulators as an approach to nicotinic acetylcholine receptor-targeted therapeutics: advantages and limitations.

Authors:  Dustin K Williams; Jingyi Wang; Roger L Papke
Journal:  Biochem Pharmacol       Date:  2011-05-14       Impact factor: 5.858

10.  Positive allosteric modulation of alpha7 neuronal nicotinic acetylcholine receptors: lack of cytotoxicity in PC12 cells and rat primary cortical neurons.

Authors:  Min Hu; Murali Gopalakrishnan; Jinhe Li
Journal:  Br J Pharmacol       Date:  2009-12       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.